Details of the Drug
General Information of Drug (ID: DMX8DZM)
Drug Name |
7-chloro-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
7-chloro-1H-indazole; 37435-12-4; 7-Chloroindazole; 1H-Indazole, 7-chloro-; CHEMBL247367; AK-24465; 7-chlor-1H-indazol; ACMC-1AG86; SCHEMBL104360; SCHEMBL19152469; CTK1C1806; DTXSID80455690; WIYOYUQVNPTVQG-UHFFFAOYSA-N; MolPort-001-767-757; 7-Chloro-1H-indazole, AldrichCPR; ZX-AT002536; BCP27378; BDBM50209244; ZINC12336533; STL554161; SBB054730; MFCD07368214; ANW-28635; OR3680; FCH921470; BBL100367; AKOS024124979; AKOS005072025; VI20076; RP01758; MCULE-5657266195; CB-0833; PB17411; ACM37435124; KB-46237; SC-27673; QC-11238; BL000561; AN-17144
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 152.58 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||